Global Dual GLP-1R/GIPR Agonist Market Growth 2026-2032
The global Dual GLP-1R/GIPR Agonist market size is predicted to grow from US$ 29966 million in 2025 to US$ 64976 million in 2032; it is expected to grow at a CAGR of 11.6% from 2026 to 2032.
In 2025, global Dual GLP-1R/GIPR Agonist production reached approximately 161.44 M Units, with an average global market price of around 190 USD per Unit.
A Dual GLP-1R/GIPR Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available Dual GLP-1R/GIPR Agonist product in the world.
Dual GLP-1R/GIPR Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.
The upstream raw materials for Dual GLP-1R/GIPR Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.
The single-line production capacity of Dual GLP-1R/GIPR Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
United States market for Dual GLP-1R/GIPR Agonist is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Dual GLP-1R/GIPR Agonist is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Dual GLP-1R/GIPR Agonist is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Dual GLP-1R/GIPR Agonist players cover Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Dual GLP-1R/GIPR Agonist Industry Forecast” looks at past sales and reviews total world Dual GLP-1R/GIPR Agonist sales in 2025, providing a comprehensive analysis by region and market sector of projected Dual GLP-1R/GIPR Agonist sales for 2026 through 2032. With Dual GLP-1R/GIPR Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dual GLP-1R/GIPR Agonist industry.
This Insight Report provides a comprehensive analysis of the global Dual GLP-1R/GIPR Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dual GLP-1R/GIPR Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dual GLP-1R/GIPR Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dual GLP-1R/GIPR Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dual GLP-1R/GIPR Agonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Dual GLP-1R/GIPR Agonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Dual GLP-1R/GIPR Agonist market?
What factors are driving Dual GLP-1R/GIPR Agonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dual GLP-1R/GIPR Agonist market opportunities vary by end market size?
How does Dual GLP-1R/GIPR Agonist break out by Type, by Application?
In 2025, global Dual GLP-1R/GIPR Agonist production reached approximately 161.44 M Units, with an average global market price of around 190 USD per Unit.
A Dual GLP-1R/GIPR Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available Dual GLP-1R/GIPR Agonist product in the world.
Dual GLP-1R/GIPR Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.
The upstream raw materials for Dual GLP-1R/GIPR Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.
The single-line production capacity of Dual GLP-1R/GIPR Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
United States market for Dual GLP-1R/GIPR Agonist is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Dual GLP-1R/GIPR Agonist is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Dual GLP-1R/GIPR Agonist is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Dual GLP-1R/GIPR Agonist players cover Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Dual GLP-1R/GIPR Agonist Industry Forecast” looks at past sales and reviews total world Dual GLP-1R/GIPR Agonist sales in 2025, providing a comprehensive analysis by region and market sector of projected Dual GLP-1R/GIPR Agonist sales for 2026 through 2032. With Dual GLP-1R/GIPR Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dual GLP-1R/GIPR Agonist industry.
This Insight Report provides a comprehensive analysis of the global Dual GLP-1R/GIPR Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dual GLP-1R/GIPR Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dual GLP-1R/GIPR Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dual GLP-1R/GIPR Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dual GLP-1R/GIPR Agonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Dual GLP-1R/GIPR Agonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Injection
- Oral Administration
- Others
- Balanced
- Biased
- Others
- Long-acting
- Short-acting
- Diabetes
- Obesity
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Eli Lilly
- Roche
- Viking Therapeutics
- Ascletis Pharma
- Jiangsu Hengrui Medicine
- East China Pharmaceutical
- Tonghua Dongbao Pharmaceutical
- Lepu Medical Technology
- Hansoh Pharma
What is the 10-year outlook for the global Dual GLP-1R/GIPR Agonist market?
What factors are driving Dual GLP-1R/GIPR Agonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dual GLP-1R/GIPR Agonist market opportunities vary by end market size?
How does Dual GLP-1R/GIPR Agonist break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Dual GLP-1R/GIPR Agonist Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Dual GLP-1R/GIPR Agonist by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Dual GLP-1R/GIPR Agonist by Country/Region, 2021, 2025 & 2032
2.2 Dual GLP-1R/GIPR Agonist Segment by Type
2.2.1 Injection
2.2.2 Oral Administration
2.2.3 Others
2.2.4 Dual GLP-1R/GIPR Agonist Sales by Type
2.2.4.1 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
2.2.4.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Type (2021-2026)
2.3 Dual GLP-1R/GIPR Agonist Segment by Receptor Agonist Properties
2.3.1 Balanced
2.3.2 Biased
2.3.3 Others
2.3.4 Dual GLP-1R/GIPR Agonist Sales by Receptor Agonist Properties
2.3.4.1 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Receptor Agonist Properties (2021-2026)
2.3.4.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Receptor Agonist Properties (2021-2026)
2.3.4.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Receptor Agonist Properties (2021-2026)
2.4 Dual GLP-1R/GIPR Agonist Segment by Medicinal Efficacy
2.4.1 Long-acting
2.4.2 Short-acting
2.4.3 Dual GLP-1R/GIPR Agonist Sales by Medicinal Efficacy
2.4.3.1 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Medicinal Efficacy (2021-2026)
2.4.3.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Medicinal Efficacy (2021-2026)
2.4.3.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Medicinal Efficacy (2021-2026)
2.5 Dual GLP-1R/GIPR Agonist Segment by Application
2.5.1 Diabetes
2.5.2 Obesity
2.5.3 Others
2.5.4 Dual GLP-1R/GIPR Agonist Sales by Application
2.5.4.1 Global Dual GLP-1R/GIPR Agonist Sale Market Share by Application (2021-2026)
2.5.4.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Dual GLP-1R/GIPR Agonist Breakdown Data by Company
3.1.1 Global Dual GLP-1R/GIPR Agonist Annual Sales by Company (2021-2026)
3.1.2 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Company (2021-2026)
3.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue by Company (2021-2026)
3.2.1 Global Dual GLP-1R/GIPR Agonist Revenue by Company (2021-2026)
3.2.2 Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Company (2021-2026)
3.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Company
3.4 Key Manufacturers Dual GLP-1R/GIPR Agonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Dual GLP-1R/GIPR Agonist Product Location Distribution
3.4.2 Players Dual GLP-1R/GIPR Agonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DUAL GLP-1R/GIPR AGONIST BY GEOGRAPHIC REGION
4.1 World Historic Dual GLP-1R/GIPR Agonist Market Size by Geographic Region (2021-2026)
4.1.1 Global Dual GLP-1R/GIPR Agonist Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Dual GLP-1R/GIPR Agonist Market Size by Country/Region (2021-2026)
4.2.1 Global Dual GLP-1R/GIPR Agonist Annual Sales by Country/Region (2021-2026)
4.2.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue by Country/Region (2021-2026)
4.3 Americas Dual GLP-1R/GIPR Agonist Sales Growth
4.4 APAC Dual GLP-1R/GIPR Agonist Sales Growth
4.5 Europe Dual GLP-1R/GIPR Agonist Sales Growth
4.6 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Growth
5 AMERICAS
5.1 Americas Dual GLP-1R/GIPR Agonist Sales by Country
5.1.1 Americas Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026)
5.1.2 Americas Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026)
5.2 Americas Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
5.3 Americas Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dual GLP-1R/GIPR Agonist Sales by Region
6.1.1 APAC Dual GLP-1R/GIPR Agonist Sales by Region (2021-2026)
6.1.2 APAC Dual GLP-1R/GIPR Agonist Revenue by Region (2021-2026)
6.2 APAC Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
6.3 APAC Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Dual GLP-1R/GIPR Agonist by Country
7.1.1 Europe Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026)
7.1.2 Europe Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026)
7.2 Europe Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
7.3 Europe Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Dual GLP-1R/GIPR Agonist by Country
8.1.1 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026)
8.1.2 Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026)
8.2 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
8.3 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Dual GLP-1R/GIPR Agonist
10.3 Manufacturing Process Analysis of Dual GLP-1R/GIPR Agonist
10.4 Industry Chain Structure of Dual GLP-1R/GIPR Agonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Dual GLP-1R/GIPR Agonist Distributors
11.3 Dual GLP-1R/GIPR Agonist Customer
12 WORLD FORECAST REVIEW FOR DUAL GLP-1R/GIPR AGONIST BY GEOGRAPHIC REGION
12.1 Global Dual GLP-1R/GIPR Agonist Market Size Forecast by Region
12.1.1 Global Dual GLP-1R/GIPR Agonist Forecast by Region (2027-2032)
12.1.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Dual GLP-1R/GIPR Agonist Forecast by Type (2027-2032)
12.7 Global Dual GLP-1R/GIPR Agonist Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.1.3 Eli Lilly Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.2.3 Roche Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Viking Therapeutics
13.3.1 Viking Therapeutics Company Information
13.3.2 Viking Therapeutics Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.3.3 Viking Therapeutics Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Viking Therapeutics Main Business Overview
13.3.5 Viking Therapeutics Latest Developments
13.4 Ascletis Pharma
13.4.1 Ascletis Pharma Company Information
13.4.2 Ascletis Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.4.3 Ascletis Pharma Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ascletis Pharma Main Business Overview
13.4.5 Ascletis Pharma Latest Developments
13.5 Jiangsu Hengrui Medicine
13.5.1 Jiangsu Hengrui Medicine Company Information
13.5.2 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.5.3 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Jiangsu Hengrui Medicine Main Business Overview
13.5.5 Jiangsu Hengrui Medicine Latest Developments
13.6 East China Pharmaceutical
13.6.1 East China Pharmaceutical Company Information
13.6.2 East China Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.6.3 East China Pharmaceutical Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 East China Pharmaceutical Main Business Overview
13.6.5 East China Pharmaceutical Latest Developments
13.7 Tonghua Dongbao Pharmaceutical
13.7.1 Tonghua Dongbao Pharmaceutical Company Information
13.7.2 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.7.3 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.7.5 Tonghua Dongbao Pharmaceutical Latest Developments
13.8 Lepu Medical Technology
13.8.1 Lepu Medical Technology Company Information
13.8.2 Lepu Medical Technology Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.8.3 Lepu Medical Technology Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Lepu Medical Technology Main Business Overview
13.8.5 Lepu Medical Technology Latest Developments
13.9 Hansoh Pharma
13.9.1 Hansoh Pharma Company Information
13.9.2 Hansoh Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.9.3 Hansoh Pharma Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Hansoh Pharma Main Business Overview
13.9.5 Hansoh Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Dual GLP-1R/GIPR Agonist Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Dual GLP-1R/GIPR Agonist by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Dual GLP-1R/GIPR Agonist by Country/Region, 2021, 2025 & 2032
2.2 Dual GLP-1R/GIPR Agonist Segment by Type
2.2.1 Injection
2.2.2 Oral Administration
2.2.3 Others
2.2.4 Dual GLP-1R/GIPR Agonist Sales by Type
2.2.4.1 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
2.2.4.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Type (2021-2026)
2.3 Dual GLP-1R/GIPR Agonist Segment by Receptor Agonist Properties
2.3.1 Balanced
2.3.2 Biased
2.3.3 Others
2.3.4 Dual GLP-1R/GIPR Agonist Sales by Receptor Agonist Properties
2.3.4.1 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Receptor Agonist Properties (2021-2026)
2.3.4.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Receptor Agonist Properties (2021-2026)
2.3.4.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Receptor Agonist Properties (2021-2026)
2.4 Dual GLP-1R/GIPR Agonist Segment by Medicinal Efficacy
2.4.1 Long-acting
2.4.2 Short-acting
2.4.3 Dual GLP-1R/GIPR Agonist Sales by Medicinal Efficacy
2.4.3.1 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Medicinal Efficacy (2021-2026)
2.4.3.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Medicinal Efficacy (2021-2026)
2.4.3.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Medicinal Efficacy (2021-2026)
2.5 Dual GLP-1R/GIPR Agonist Segment by Application
2.5.1 Diabetes
2.5.2 Obesity
2.5.3 Others
2.5.4 Dual GLP-1R/GIPR Agonist Sales by Application
2.5.4.1 Global Dual GLP-1R/GIPR Agonist Sale Market Share by Application (2021-2026)
2.5.4.2 Global Dual GLP-1R/GIPR Agonist Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Dual GLP-1R/GIPR Agonist Breakdown Data by Company
3.1.1 Global Dual GLP-1R/GIPR Agonist Annual Sales by Company (2021-2026)
3.1.2 Global Dual GLP-1R/GIPR Agonist Sales Market Share by Company (2021-2026)
3.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue by Company (2021-2026)
3.2.1 Global Dual GLP-1R/GIPR Agonist Revenue by Company (2021-2026)
3.2.2 Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Company (2021-2026)
3.3 Global Dual GLP-1R/GIPR Agonist Sale Price by Company
3.4 Key Manufacturers Dual GLP-1R/GIPR Agonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Dual GLP-1R/GIPR Agonist Product Location Distribution
3.4.2 Players Dual GLP-1R/GIPR Agonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DUAL GLP-1R/GIPR AGONIST BY GEOGRAPHIC REGION
4.1 World Historic Dual GLP-1R/GIPR Agonist Market Size by Geographic Region (2021-2026)
4.1.1 Global Dual GLP-1R/GIPR Agonist Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Dual GLP-1R/GIPR Agonist Market Size by Country/Region (2021-2026)
4.2.1 Global Dual GLP-1R/GIPR Agonist Annual Sales by Country/Region (2021-2026)
4.2.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue by Country/Region (2021-2026)
4.3 Americas Dual GLP-1R/GIPR Agonist Sales Growth
4.4 APAC Dual GLP-1R/GIPR Agonist Sales Growth
4.5 Europe Dual GLP-1R/GIPR Agonist Sales Growth
4.6 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Growth
5 AMERICAS
5.1 Americas Dual GLP-1R/GIPR Agonist Sales by Country
5.1.1 Americas Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026)
5.1.2 Americas Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026)
5.2 Americas Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
5.3 Americas Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dual GLP-1R/GIPR Agonist Sales by Region
6.1.1 APAC Dual GLP-1R/GIPR Agonist Sales by Region (2021-2026)
6.1.2 APAC Dual GLP-1R/GIPR Agonist Revenue by Region (2021-2026)
6.2 APAC Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
6.3 APAC Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Dual GLP-1R/GIPR Agonist by Country
7.1.1 Europe Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026)
7.1.2 Europe Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026)
7.2 Europe Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
7.3 Europe Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Dual GLP-1R/GIPR Agonist by Country
8.1.1 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026)
8.1.2 Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026)
8.2 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026)
8.3 Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Dual GLP-1R/GIPR Agonist
10.3 Manufacturing Process Analysis of Dual GLP-1R/GIPR Agonist
10.4 Industry Chain Structure of Dual GLP-1R/GIPR Agonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Dual GLP-1R/GIPR Agonist Distributors
11.3 Dual GLP-1R/GIPR Agonist Customer
12 WORLD FORECAST REVIEW FOR DUAL GLP-1R/GIPR AGONIST BY GEOGRAPHIC REGION
12.1 Global Dual GLP-1R/GIPR Agonist Market Size Forecast by Region
12.1.1 Global Dual GLP-1R/GIPR Agonist Forecast by Region (2027-2032)
12.1.2 Global Dual GLP-1R/GIPR Agonist Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Dual GLP-1R/GIPR Agonist Forecast by Type (2027-2032)
12.7 Global Dual GLP-1R/GIPR Agonist Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.1.3 Eli Lilly Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 Roche
13.2.1 Roche Company Information
13.2.2 Roche Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.2.3 Roche Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Roche Main Business Overview
13.2.5 Roche Latest Developments
13.3 Viking Therapeutics
13.3.1 Viking Therapeutics Company Information
13.3.2 Viking Therapeutics Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.3.3 Viking Therapeutics Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Viking Therapeutics Main Business Overview
13.3.5 Viking Therapeutics Latest Developments
13.4 Ascletis Pharma
13.4.1 Ascletis Pharma Company Information
13.4.2 Ascletis Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.4.3 Ascletis Pharma Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ascletis Pharma Main Business Overview
13.4.5 Ascletis Pharma Latest Developments
13.5 Jiangsu Hengrui Medicine
13.5.1 Jiangsu Hengrui Medicine Company Information
13.5.2 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.5.3 Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Jiangsu Hengrui Medicine Main Business Overview
13.5.5 Jiangsu Hengrui Medicine Latest Developments
13.6 East China Pharmaceutical
13.6.1 East China Pharmaceutical Company Information
13.6.2 East China Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.6.3 East China Pharmaceutical Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 East China Pharmaceutical Main Business Overview
13.6.5 East China Pharmaceutical Latest Developments
13.7 Tonghua Dongbao Pharmaceutical
13.7.1 Tonghua Dongbao Pharmaceutical Company Information
13.7.2 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.7.3 Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.7.5 Tonghua Dongbao Pharmaceutical Latest Developments
13.8 Lepu Medical Technology
13.8.1 Lepu Medical Technology Company Information
13.8.2 Lepu Medical Technology Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.8.3 Lepu Medical Technology Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Lepu Medical Technology Main Business Overview
13.8.5 Lepu Medical Technology Latest Developments
13.9 Hansoh Pharma
13.9.1 Hansoh Pharma Company Information
13.9.2 Hansoh Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
13.9.3 Hansoh Pharma Dual GLP-1R/GIPR Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Hansoh Pharma Main Business Overview
13.9.5 Hansoh Pharma Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Dual GLP-1R/GIPR Agonist Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Dual GLP-1R/GIPR Agonist Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Injection
Table 4. Major Players of Oral Administration
Table 5. Major Players of Others
Table 6. Global Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 7. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Table 8. Global Dual GLP-1R/GIPR Agonist Revenue by Type (2021-2026) & ($ million)
Table 9. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Type (2021-2026)
Table 10. Global Dual GLP-1R/GIPR Agonist Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Balanced
Table 12. Major Players of Biased
Table 13. Major Players of Others
Table 14. Global Dual GLP-1R/GIPR Agonist Sales by Receptor Agonist Properties (2021-2026) & (K Units)
Table 15. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Receptor Agonist Properties (2021-2026)
Table 16. Global Dual GLP-1R/GIPR Agonist Revenue by Receptor Agonist Properties (2021-2026) & ($ million)
Table 17. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Receptor Agonist Properties (2021-2026)
Table 18. Global Dual GLP-1R/GIPR Agonist Sale Price by Receptor Agonist Properties (2021-2026) & (US$/Unit)
Table 19. Major Players of Long-acting
Table 20. Major Players of Short-acting
Table 21. Global Dual GLP-1R/GIPR Agonist Sales by Medicinal Efficacy (2021-2026) & (K Units)
Table 22. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Medicinal Efficacy (2021-2026)
Table 23. Global Dual GLP-1R/GIPR Agonist Revenue by Medicinal Efficacy (2021-2026) & ($ million)
Table 24. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Medicinal Efficacy (2021-2026)
Table 25. Global Dual GLP-1R/GIPR Agonist Sale Price by Medicinal Efficacy (2021-2026) & (US$/Unit)
Table 26. Global Dual GLP-1R/GIPR Agonist Sale by Application (2021-2026) & (K Units)
Table 27. Global Dual GLP-1R/GIPR Agonist Sale Market Share by Application (2021-2026)
Table 28. Global Dual GLP-1R/GIPR Agonist Revenue by Application (2021-2026) & ($ million)
Table 29. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Application (2021-2026)
Table 30. Global Dual GLP-1R/GIPR Agonist Sale Price by Application (2021-2026) & (US$/Unit)
Table 31. Global Dual GLP-1R/GIPR Agonist Sales by Company (2021-2026) & (K Units)
Table 32. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Company (2021-2026)
Table 33. Global Dual GLP-1R/GIPR Agonist Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Company (2021-2026)
Table 35. Global Dual GLP-1R/GIPR Agonist Sale Price by Company (2021-2026) & (US$/Unit)
Table 36. Key Manufacturers Dual GLP-1R/GIPR Agonist Producing Area Distribution and Sales Area
Table 37. Players Dual GLP-1R/GIPR Agonist Products Offered
Table 38. Dual GLP-1R/GIPR Agonist Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Dual GLP-1R/GIPR Agonist Sales by Geographic Region (2021-2026) & (K Units)
Table 42. Global Dual GLP-1R/GIPR Agonist Sales Market Share Geographic Region (2021-2026)
Table 43. Global Dual GLP-1R/GIPR Agonist Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Dual GLP-1R/GIPR Agonist Sales by Country/Region (2021-2026) & (K Units)
Table 46. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Country/Region (2021-2026)
Table 47. Global Dual GLP-1R/GIPR Agonist Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026) & (K Units)
Table 50. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Country (2021-2026)
Table 51. Americas Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 53. Americas Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 54. APAC Dual GLP-1R/GIPR Agonist Sales by Region (2021-2026) & (K Units)
Table 55. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Region (2021-2026)
Table 56. APAC Dual GLP-1R/GIPR Agonist Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 58. APAC Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 59. Europe Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026) & (K Units)
Table 60. Europe Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 62. Europe Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 63. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026) & (K Units)
Table 64. Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 66. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 67. Key Market Drivers & Growth Opportunities of Dual GLP-1R/GIPR Agonist
Table 68. Key Market Challenges & Risks of Dual GLP-1R/GIPR Agonist
Table 69. Key Industry Trends of Dual GLP-1R/GIPR Agonist
Table 70. Dual GLP-1R/GIPR Agonist Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Dual GLP-1R/GIPR Agonist Distributors List
Table 73. Dual GLP-1R/GIPR Agonist Customer List
Table 74. Global Dual GLP-1R/GIPR Agonist Sales Forecast by Region (2027-2032) & (K Units)
Table 75. Global Dual GLP-1R/GIPR Agonist Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Dual GLP-1R/GIPR Agonist Sales Forecast by Country (2027-2032) & (K Units)
Table 77. Americas Dual GLP-1R/GIPR Agonist Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Dual GLP-1R/GIPR Agonist Sales Forecast by Region (2027-2032) & (K Units)
Table 79. APAC Dual GLP-1R/GIPR Agonist Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Dual GLP-1R/GIPR Agonist Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Europe Dual GLP-1R/GIPR Agonist Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Forecast by Country (2027-2032) & (K Units)
Table 83. Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Dual GLP-1R/GIPR Agonist Sales Forecast by Type (2027-2032) & (K Units)
Table 85. Global Dual GLP-1R/GIPR Agonist Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Dual GLP-1R/GIPR Agonist Sales Forecast by Application (2027-2032) & (K Units)
Table 87. Global Dual GLP-1R/GIPR Agonist Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Eli Lilly Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 89. Eli Lilly Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 90. Eli Lilly Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Eli Lilly Main Business
Table 92. Eli Lilly Latest Developments
Table 93. Roche Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 94. Roche Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 95. Roche Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Roche Main Business
Table 97. Roche Latest Developments
Table 98. Viking Therapeutics Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 99. Viking Therapeutics Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 100. Viking Therapeutics Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Viking Therapeutics Main Business
Table 102. Viking Therapeutics Latest Developments
Table 103. Ascletis Pharma Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 104. Ascletis Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 105. Ascletis Pharma Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Ascletis Pharma Main Business
Table 107. Ascletis Pharma Latest Developments
Table 108. Jiangsu Hengrui Medicine Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 109. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 110. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Jiangsu Hengrui Medicine Main Business
Table 112. Jiangsu Hengrui Medicine Latest Developments
Table 113. East China Pharmaceutical Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 114. East China Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 115. East China Pharmaceutical Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. East China Pharmaceutical Main Business
Table 117. East China Pharmaceutical Latest Developments
Table 118. Tonghua Dongbao Pharmaceutical Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 119. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 120. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Tonghua Dongbao Pharmaceutical Main Business
Table 122. Tonghua Dongbao Pharmaceutical Latest Developments
Table 123. Lepu Medical Technology Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 124. Lepu Medical Technology Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 125. Lepu Medical Technology Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Lepu Medical Technology Main Business
Table 127. Lepu Medical Technology Latest Developments
Table 128. Hansoh Pharma Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 129. Hansoh Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 130. Hansoh Pharma Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Hansoh Pharma Main Business
Table 132. Hansoh Pharma Latest Developments
Table 1. Dual GLP-1R/GIPR Agonist Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Dual GLP-1R/GIPR Agonist Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Injection
Table 4. Major Players of Oral Administration
Table 5. Major Players of Others
Table 6. Global Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 7. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Table 8. Global Dual GLP-1R/GIPR Agonist Revenue by Type (2021-2026) & ($ million)
Table 9. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Type (2021-2026)
Table 10. Global Dual GLP-1R/GIPR Agonist Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Balanced
Table 12. Major Players of Biased
Table 13. Major Players of Others
Table 14. Global Dual GLP-1R/GIPR Agonist Sales by Receptor Agonist Properties (2021-2026) & (K Units)
Table 15. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Receptor Agonist Properties (2021-2026)
Table 16. Global Dual GLP-1R/GIPR Agonist Revenue by Receptor Agonist Properties (2021-2026) & ($ million)
Table 17. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Receptor Agonist Properties (2021-2026)
Table 18. Global Dual GLP-1R/GIPR Agonist Sale Price by Receptor Agonist Properties (2021-2026) & (US$/Unit)
Table 19. Major Players of Long-acting
Table 20. Major Players of Short-acting
Table 21. Global Dual GLP-1R/GIPR Agonist Sales by Medicinal Efficacy (2021-2026) & (K Units)
Table 22. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Medicinal Efficacy (2021-2026)
Table 23. Global Dual GLP-1R/GIPR Agonist Revenue by Medicinal Efficacy (2021-2026) & ($ million)
Table 24. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Medicinal Efficacy (2021-2026)
Table 25. Global Dual GLP-1R/GIPR Agonist Sale Price by Medicinal Efficacy (2021-2026) & (US$/Unit)
Table 26. Global Dual GLP-1R/GIPR Agonist Sale by Application (2021-2026) & (K Units)
Table 27. Global Dual GLP-1R/GIPR Agonist Sale Market Share by Application (2021-2026)
Table 28. Global Dual GLP-1R/GIPR Agonist Revenue by Application (2021-2026) & ($ million)
Table 29. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Application (2021-2026)
Table 30. Global Dual GLP-1R/GIPR Agonist Sale Price by Application (2021-2026) & (US$/Unit)
Table 31. Global Dual GLP-1R/GIPR Agonist Sales by Company (2021-2026) & (K Units)
Table 32. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Company (2021-2026)
Table 33. Global Dual GLP-1R/GIPR Agonist Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Company (2021-2026)
Table 35. Global Dual GLP-1R/GIPR Agonist Sale Price by Company (2021-2026) & (US$/Unit)
Table 36. Key Manufacturers Dual GLP-1R/GIPR Agonist Producing Area Distribution and Sales Area
Table 37. Players Dual GLP-1R/GIPR Agonist Products Offered
Table 38. Dual GLP-1R/GIPR Agonist Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Dual GLP-1R/GIPR Agonist Sales by Geographic Region (2021-2026) & (K Units)
Table 42. Global Dual GLP-1R/GIPR Agonist Sales Market Share Geographic Region (2021-2026)
Table 43. Global Dual GLP-1R/GIPR Agonist Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Dual GLP-1R/GIPR Agonist Sales by Country/Region (2021-2026) & (K Units)
Table 46. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Country/Region (2021-2026)
Table 47. Global Dual GLP-1R/GIPR Agonist Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026) & (K Units)
Table 50. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Country (2021-2026)
Table 51. Americas Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 53. Americas Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 54. APAC Dual GLP-1R/GIPR Agonist Sales by Region (2021-2026) & (K Units)
Table 55. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Region (2021-2026)
Table 56. APAC Dual GLP-1R/GIPR Agonist Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 58. APAC Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 59. Europe Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026) & (K Units)
Table 60. Europe Dual GLP-1R/GIPR Agonist Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 62. Europe Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 63. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Country (2021-2026) & (K Units)
Table 64. Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Type (2021-2026) & (K Units)
Table 66. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales by Application (2021-2026) & (K Units)
Table 67. Key Market Drivers & Growth Opportunities of Dual GLP-1R/GIPR Agonist
Table 68. Key Market Challenges & Risks of Dual GLP-1R/GIPR Agonist
Table 69. Key Industry Trends of Dual GLP-1R/GIPR Agonist
Table 70. Dual GLP-1R/GIPR Agonist Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Dual GLP-1R/GIPR Agonist Distributors List
Table 73. Dual GLP-1R/GIPR Agonist Customer List
Table 74. Global Dual GLP-1R/GIPR Agonist Sales Forecast by Region (2027-2032) & (K Units)
Table 75. Global Dual GLP-1R/GIPR Agonist Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Dual GLP-1R/GIPR Agonist Sales Forecast by Country (2027-2032) & (K Units)
Table 77. Americas Dual GLP-1R/GIPR Agonist Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Dual GLP-1R/GIPR Agonist Sales Forecast by Region (2027-2032) & (K Units)
Table 79. APAC Dual GLP-1R/GIPR Agonist Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Dual GLP-1R/GIPR Agonist Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Europe Dual GLP-1R/GIPR Agonist Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Forecast by Country (2027-2032) & (K Units)
Table 83. Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Dual GLP-1R/GIPR Agonist Sales Forecast by Type (2027-2032) & (K Units)
Table 85. Global Dual GLP-1R/GIPR Agonist Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Dual GLP-1R/GIPR Agonist Sales Forecast by Application (2027-2032) & (K Units)
Table 87. Global Dual GLP-1R/GIPR Agonist Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Eli Lilly Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 89. Eli Lilly Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 90. Eli Lilly Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Eli Lilly Main Business
Table 92. Eli Lilly Latest Developments
Table 93. Roche Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 94. Roche Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 95. Roche Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Roche Main Business
Table 97. Roche Latest Developments
Table 98. Viking Therapeutics Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 99. Viking Therapeutics Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 100. Viking Therapeutics Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Viking Therapeutics Main Business
Table 102. Viking Therapeutics Latest Developments
Table 103. Ascletis Pharma Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 104. Ascletis Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 105. Ascletis Pharma Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Ascletis Pharma Main Business
Table 107. Ascletis Pharma Latest Developments
Table 108. Jiangsu Hengrui Medicine Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 109. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 110. Jiangsu Hengrui Medicine Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Jiangsu Hengrui Medicine Main Business
Table 112. Jiangsu Hengrui Medicine Latest Developments
Table 113. East China Pharmaceutical Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 114. East China Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 115. East China Pharmaceutical Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. East China Pharmaceutical Main Business
Table 117. East China Pharmaceutical Latest Developments
Table 118. Tonghua Dongbao Pharmaceutical Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 119. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 120. Tonghua Dongbao Pharmaceutical Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Tonghua Dongbao Pharmaceutical Main Business
Table 122. Tonghua Dongbao Pharmaceutical Latest Developments
Table 123. Lepu Medical Technology Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 124. Lepu Medical Technology Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 125. Lepu Medical Technology Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Lepu Medical Technology Main Business
Table 127. Lepu Medical Technology Latest Developments
Table 128. Hansoh Pharma Basic Information, Dual GLP-1R/GIPR Agonist Manufacturing Base, Sales Area and Its Competitors
Table 129. Hansoh Pharma Dual GLP-1R/GIPR Agonist Product Portfolios and Specifications
Table 130. Hansoh Pharma Dual GLP-1R/GIPR Agonist Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Hansoh Pharma Main Business
Table 132. Hansoh Pharma Latest Developments
LIST OF FIGURES
Figure 1. Picture of Dual GLP-1R/GIPR Agonist
Figure 2. Dual GLP-1R/GIPR Agonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Dual GLP-1R/GIPR Agonist Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Dual GLP-1R/GIPR Agonist Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Dual GLP-1R/GIPR Agonist Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Dual GLP-1R/GIPR Agonist Sales Market Share by Country/Region (2025)
Figure 10. Dual GLP-1R/GIPR Agonist Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Injection
Figure 12. Product Picture of Oral Administration
Figure 13. Product Picture of Others
Figure 14. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Type in 2026
Figure 15. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Balanced
Figure 17. Product Picture of Biased
Figure 18. Product Picture of Others
Figure 19. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Receptor Agonist Properties in 2026
Figure 20. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Receptor Agonist Properties (2021-2026)
Figure 21. Product Picture of Long-acting
Figure 22. Product Picture of Short-acting
Figure 23. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Medicinal Efficacy in 2026
Figure 24. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Medicinal Efficacy (2021-2026)
Figure 25. Dual GLP-1R/GIPR Agonist Consumed in Diabetes
Figure 26. Global Dual GLP-1R/GIPR Agonist Market: Diabetes (2021-2026) & (K Units)
Figure 27. Dual GLP-1R/GIPR Agonist Consumed in Obesity
Figure 28. Global Dual GLP-1R/GIPR Agonist Market: Obesity (2021-2026) & (K Units)
Figure 29. Dual GLP-1R/GIPR Agonist Consumed in Others
Figure 30. Global Dual GLP-1R/GIPR Agonist Market: Others (2021-2026) & (K Units)
Figure 31. Global Dual GLP-1R/GIPR Agonist Sale Market Share by Application (2025)
Figure 32. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Application in 2026
Figure 33. Dual GLP-1R/GIPR Agonist Sales by Company in 2026 (K Units)
Figure 34. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Company in 2026
Figure 35. Dual GLP-1R/GIPR Agonist Revenue by Company in 2026 ($ millions)
Figure 36. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Company in 2026
Figure 37. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Geographic Region in 2026
Figure 39. Americas Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 40. Americas Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 41. APAC Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 42. APAC Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 43. Europe Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 44. Europe Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 46. Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 47. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Country in 2026
Figure 48. Americas Dual GLP-1R/GIPR Agonist Revenue Market Share by Country (2021-2026)
Figure 49. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 50. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 51. United States Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Region in 2026
Figure 56. APAC Dual GLP-1R/GIPR Agonist Revenue Market Share by Region (2021-2026)
Figure 57. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 58. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 59. China Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 63. India Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Dual GLP-1R/GIPR Agonist Sales Market Share by Country in 2026
Figure 67. Europe Dual GLP-1R/GIPR Agonist Revenue Market Share by Country (2021-2026)
Figure 68. Europe Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 69. Europe Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 70. Germany Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 71. France Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 78. Egypt Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Dual GLP-1R/GIPR Agonist in 2026
Figure 84. Manufacturing Process Analysis of Dual GLP-1R/GIPR Agonist
Figure 85. Industry Chain Structure of Dual GLP-1R/GIPR Agonist
Figure 86. Channels of Distribution
Figure 87. Global Dual GLP-1R/GIPR Agonist Sales Market Forecast by Region (2027-2032)
Figure 88. Global Dual GLP-1R/GIPR Agonist Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Dual GLP-1R/GIPR Agonist Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Dual GLP-1R/GIPR Agonist Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Dual GLP-1R/GIPR Agonist Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Dual GLP-1R/GIPR Agonist Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Dual GLP-1R/GIPR Agonist
Figure 2. Dual GLP-1R/GIPR Agonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Dual GLP-1R/GIPR Agonist Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Dual GLP-1R/GIPR Agonist Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Dual GLP-1R/GIPR Agonist Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Dual GLP-1R/GIPR Agonist Sales Market Share by Country/Region (2025)
Figure 10. Dual GLP-1R/GIPR Agonist Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Injection
Figure 12. Product Picture of Oral Administration
Figure 13. Product Picture of Others
Figure 14. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Type in 2026
Figure 15. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Balanced
Figure 17. Product Picture of Biased
Figure 18. Product Picture of Others
Figure 19. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Receptor Agonist Properties in 2026
Figure 20. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Receptor Agonist Properties (2021-2026)
Figure 21. Product Picture of Long-acting
Figure 22. Product Picture of Short-acting
Figure 23. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Medicinal Efficacy in 2026
Figure 24. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Medicinal Efficacy (2021-2026)
Figure 25. Dual GLP-1R/GIPR Agonist Consumed in Diabetes
Figure 26. Global Dual GLP-1R/GIPR Agonist Market: Diabetes (2021-2026) & (K Units)
Figure 27. Dual GLP-1R/GIPR Agonist Consumed in Obesity
Figure 28. Global Dual GLP-1R/GIPR Agonist Market: Obesity (2021-2026) & (K Units)
Figure 29. Dual GLP-1R/GIPR Agonist Consumed in Others
Figure 30. Global Dual GLP-1R/GIPR Agonist Market: Others (2021-2026) & (K Units)
Figure 31. Global Dual GLP-1R/GIPR Agonist Sale Market Share by Application (2025)
Figure 32. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Application in 2026
Figure 33. Dual GLP-1R/GIPR Agonist Sales by Company in 2026 (K Units)
Figure 34. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Company in 2026
Figure 35. Dual GLP-1R/GIPR Agonist Revenue by Company in 2026 ($ millions)
Figure 36. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Company in 2026
Figure 37. Global Dual GLP-1R/GIPR Agonist Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Dual GLP-1R/GIPR Agonist Revenue Market Share by Geographic Region in 2026
Figure 39. Americas Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 40. Americas Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 41. APAC Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 42. APAC Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 43. Europe Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 44. Europe Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales 2021-2026 (K Units)
Figure 46. Middle East & Africa Dual GLP-1R/GIPR Agonist Revenue 2021-2026 ($ millions)
Figure 47. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Country in 2026
Figure 48. Americas Dual GLP-1R/GIPR Agonist Revenue Market Share by Country (2021-2026)
Figure 49. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 50. Americas Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 51. United States Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Region in 2026
Figure 56. APAC Dual GLP-1R/GIPR Agonist Revenue Market Share by Region (2021-2026)
Figure 57. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 58. APAC Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 59. China Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 63. India Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Dual GLP-1R/GIPR Agonist Sales Market Share by Country in 2026
Figure 67. Europe Dual GLP-1R/GIPR Agonist Revenue Market Share by Country (2021-2026)
Figure 68. Europe Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 69. Europe Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 70. Germany Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 71. France Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Dual GLP-1R/GIPR Agonist Sales Market Share by Application (2021-2026)
Figure 78. Egypt Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Dual GLP-1R/GIPR Agonist Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Dual GLP-1R/GIPR Agonist in 2026
Figure 84. Manufacturing Process Analysis of Dual GLP-1R/GIPR Agonist
Figure 85. Industry Chain Structure of Dual GLP-1R/GIPR Agonist
Figure 86. Channels of Distribution
Figure 87. Global Dual GLP-1R/GIPR Agonist Sales Market Forecast by Region (2027-2032)
Figure 88. Global Dual GLP-1R/GIPR Agonist Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Dual GLP-1R/GIPR Agonist Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Dual GLP-1R/GIPR Agonist Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Dual GLP-1R/GIPR Agonist Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Dual GLP-1R/GIPR Agonist Revenue Market Share Forecast by Application (2027-2032)
